XBiotech's cancer drug meets survival threshold in phase II trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to XBiotech's cancer drug meets survival threshold in phase II trial

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

October 19, 2026 9:00 AM EDT

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.

Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors.

AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored studyfunded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, Franceevaluated the addition of XBiotechs anti-IL-1 monoclonal antibody, XB2001 (Natrunix,... More